Stock DNA
Pharmaceuticals & Biotechnology
INR 11,764 Cr ()
69.00
36
0.13%
0.00
0.00%
14.31
Total Returns (Price + Dividend) 
Sudeep Pharma for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Announcement under Regulation 30 (LODR)-Change in Management
05-Oct-2026 | Source : BSEWe wish to inform the changes in the SMP of the Company arising due to completion of contractual arrangements between the company and Mr. Sendhil Pani Managing Director of Sudeep Pharma USA Inc. (Wholly Owned Subsidiary of Sudeep Pharma Limited) w.e.f. 2nd October 2026.
Closure of Trading Window
25-Sep-2026 | Source : BSEIntimation for Closure of Trading window w.e.f. 1st October 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23-Sep-2026 | Source : BSEThis is to inform that the officials of the Company will be attending the Investor Conference organized by Nuvama Emerging India CEO Forum 2026 on 28th September 2026 at 10:00 a.m. in Mumbai.
Corporate Actions 
No Upcoming Board Meetings
Sudeep Pharma Ltd has declared 150% dividend, ex-date: 23 Jul 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 14 Schemes (5.47%)
Held by 17 FIIs (1.81%)
Riva Resources Private Limited (40.35%)
Nuvama Crossover Opportunities Fund - Series Iii (2.95%)
4.89%
Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is 31.82% vs -11.20% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is 31.28% vs -4.09% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025
YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025